Business Description
Simulations Plus Inc
NAICS : 513210
SIC : 7372
ISIN : US8292141053
Total Employee Number:
213Description
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 82.35 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-EBITDA | 0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 16.77 | |||||
Beneish M-Score | -3.06 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.9 | |||||
3-Year EBITDA Growth Rate | -6.4 | |||||
3-Year EPS without NRI Growth Rate | -18.6 | |||||
3-Year FCF Growth Rate | 2.2 | |||||
3-Year Book Growth Rate | -11 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.36 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.47 | |||||
9-Day RSI | 72.16 | |||||
14-Day RSI | 68.01 | |||||
3-1 Month Momentum % | 39.87 | |||||
6-1 Month Momentum % | -7.4 | |||||
12-1 Month Momentum % | -8.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.47 | |||||
Quick Ratio | 5.47 | |||||
Cash Ratio | 3.39 | |||||
Days Sales Outstanding | 64.64 | |||||
Days Payable | 11.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 0.11 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.97 | |||||
Operating Margin % | 12.41 | |||||
Net Margin % | -77.96 | |||||
EBITDA Margin % | 20.57 | |||||
FCF Margin % | 25.78 | |||||
OCF Margin % | 30.27 | |||||
ROE % | -44.91 | |||||
ROA % | -41.74 | |||||
ROIC % | 8.16 | |||||
3-Year ROIIC % | -16.14 | |||||
ROC (Joel Greenblatt) % | 68.26 | |||||
ROCE % | 7.12 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 40.57 | |||||
PE Ratio without NRI | 20.42 | |||||
Shiller PE Ratio | 100.58 | |||||
PS Ratio | 4.61 | |||||
PB Ratio | 2.78 | |||||
Price-to-Tangible-Book | 6.01 | |||||
Price-to-Free-Cash-Flow | 17.84 | |||||
Price-to-Operating-Cash-Flow | 15.2 | |||||
EV-to-EBIT | 33.03 | |||||
EV-to-EBITDA | 19.94 | |||||
EV-to-Revenue | 4.1 | |||||
EV-to-Forward-Revenue | 4.7 | |||||
EV-to-FCF | 15.9 | |||||
Price-to-GF-Value | 0.48 | |||||
Price-to-Projected-FCF | 1.4 | |||||
Price-to-Median-PS-Value | 0.34 | |||||
Price-to-Graham-Number | 2.33 | |||||
| Price-to-Net-Current-Asset-Value | 6.78 | |||||
| Price-to-Net-Cash | 12.76 | |||||
Earnings Yield (Greenblatt) % | 3.03 | |||||
FCF Yield % | 5.59 | |||||
Forward Rate of Return (Yacktman) % | -0.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Simulations Plus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 80.535 | ||
| EPS (TTM) ($) | -3.13 | ||
| Beta | 1.4184 | ||
| 3-Year Sharpe Ratio | -0.31 | ||
| 3-Year Sortino Ratio | -0.41 | ||
| Volatility % | 54.05 | ||
| 14-Day RSI | 68.01 | ||
| 14-Day ATR ($) | 0.51503 | ||
| 20-Day SMA ($) | 17.4245 | ||
| 12-1 Month Momentum % | -8.66 | ||
| 52-Week Range ($) | 11.09 - 21.01 | ||
| Shares Outstanding (Mil) | 20.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Simulations Plus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Simulations Plus Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2026-12-01 17:00 | In 150 days | ||
| Annual report for 2026 | 2026-12-01 | In 149 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-01 | In 149 days | ||
| Third quarter earnings conference call for 2026 | 2026-07-14 17:00 | In 10 days | ||
| Third quarter earnings results for 2026 | 2026-07-14 | In 9 days | ||
| Project Optimus: Oncology Dose Optimization Based on Clinical Pharmacology Strategy and MIDD Approach | 2026-05-26 11:00 | 15.37 (+0.39%) | ||
| Second quarter earnings conference call for 2026 | 2026-04-09 17:00 | 13.00 (-1.52%) | ||
| Second quarter earnings results for 2026 | 2026-04-09 | 13.00 (-1.52%) | ||
| General meeting for 2025 | 2026-02-12 14:00 | 12.83 (-7.83%) | ||
| Clinical Pharmacology Considerations and Modeling of CAR-T Cell Therapies Using Monolix | 2026-01-22 11:00 | 20.43 (+0.15%) |
Show
Entries
Simulations Plus Inc Frequently Asked Questions
What is Simulations Plus Inc(SLP)'s stock price today?
The current price of SLP is $18.38. The 52 week high of SLP is $21.01 and 52 week low is $11.09.
When is next earnings date of Simulations Plus Inc(SLP)?
The next earnings date of Simulations Plus Inc(SLP) is 2026-07-14 Est..
Does Simulations Plus Inc(SLP) pay dividends? If so, how much?
Simulations Plus Inc(SLP) does not pay dividend.
Guru Commentaries on NAS:SLP
No articles.
Press Release
Articles on Simulations Plus Inc
No articles.
Headlines
See More- 1
Jun 17, 2026
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Benzinga • 8:13am
Jun 16, 2026
Merck and Protillion ink AI drug discovery deal worth up to $510M
Seeking Alpha • 10:42am
Altaris to Acquire Simulations Plus for $375M
Seeking Alpha • 8:34am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers